{"id":"kiacta-eprodisate-disodium","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2107338","moleculeType":"Small molecule","molecularWeight":"248.19"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eprodisate is a small molecule that interferes with the interaction between amyloid proteins and glycosaminoglycans, which are thought to play a key role in amyloid fibril formation and tissue deposition. By reducing GAG-mediated amyloid stabilization and accumulation, the drug aims to slow or halt disease progression in amyloidosis. This mechanism targets the underlying pathophysiology of amyloid diseases rather than simply managing symptoms.","oneSentence":"Eprodisate disodium inhibits glycosaminoglycan (GAG) synthesis and accumulation by blocking the formation of pathogenic protein-GAG complexes in amyloid-related diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:55.676Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Transthyretin (TTR) amyloidosis"}]},"trialDetails":[{"nctId":"NCT01215747","phase":"PHASE3","title":"Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis","status":"COMPLETED","sponsor":"C.T. Development America, Inc.","startDate":"2010-11","conditions":"Amyloidosis","enrollment":261},{"nctId":"NCT00675857","phase":"PHASE2","title":"A Phase IIa Proof-of-concept Study of NC-503 in Patients With Type II Diabetes","status":"COMPLETED","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2008-04","conditions":"Diabetes Mellitus, Type 2, Metabolic Syndrome X","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"KIACTA (eprodisate disodium)","genericName":"KIACTA (eprodisate disodium)","companyName":"C.T. Development America, Inc.","companyId":"c-t-development-america-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eprodisate disodium inhibits glycosaminoglycan (GAG) synthesis and accumulation by blocking the formation of pathogenic protein-GAG complexes in amyloid-related diseases. Used for Transthyretin (TTR) amyloidosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}